pace-cme.org Open in urlscan Pro
149.210.197.88  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Physicians' Academy for Cardiovascular Education
AgendaTopics ▼On-demandOnline-CMEPodcastsNews ▼ProgramsSlides ▼About
login

Anticoagulation ▼Diabetes & CVD ▼Heart Failure ▼Kidney disease & CVD ▼Lipids ▼




RECENT


EFFECTS OF SGLT2 INHIBITOR NOT MODIFIED BY THE COEXISTENCE OF AF IN PATIENTS
WITH HFPEF

Literature - Oct. 24, 2023 - Filippatos G, et al. - Eur J Heart Fail. 2023


HIGH AND INCREASING PREVALENCE OF CARDIO-RENAL-METABOLIC MULTIMORBIDITY

Literature - Oct. 23, 2023 - Ostrominski JW, et al. - JAMA Cardiol. 2023


2023 ESC GUIDELINE UPDATES: WHERE ARE WE WITH IRON DEFICIENCY?

10' education - Oct. 23, 2023 - Giuseppe M.C. Rosano, MD, PhD, Marco Metra, MD,
and Gianluigi Savarese, MD, PhD



QUITTING SMOKING ASSOCIATED WITH REDUCED RISK OF ADVERSE OUTCOMES AFTER PCI

Literature - Oct. 19, 2023 - Ki YJ, et al. - Eur Heart J. 2023


2023 ESC GUIDELINE UPDATES: WHERE ARE WE WITH IRON DEFICIENCY?

10' education - Oct. 23, 2023 - Giuseppe M.C. Rosano, MD, PhD, Marco Metra, MD,
and Gianluigi Savarese, MD, PhD



A PRACTICAL LOOK AT CARDIORENAL PROTECTION FOR CKD IN T2D: APPLYING RECENT DATA

15' education - Oct. 19, 2023 - Carolyn Lam, MD, PhD, Maria Luiza Caramori, MD,
PhD, Ana Maria Cebrián-Cuenca, MD, PhD, and Pam Taub, MD



A MULTIDISCIPLINARY APPROACH TO MANAGING POTASSIUM LEVELS IN PATIENTS WITH HF
WHEN OPTIMIZING RAASI THERAPY

10' education - Oct. 18, 2023 - Antoni Bayés-Genís, MD, PhD, and Patrick
Rossignol, MD, PhD



NOVEL ORAL PATHWAYS IN LDL-C LOWERING THERAPY: THE NEW PROMISE OF CETPI

10' education - Oct. 17, 2023 - Erin Michos, MD



PCSK9I: BENEFITS ACROSS THE SPECTRUM OF CARDIOVASCULAR DISEASE

10' education - Oct. 16, 2023 - Fabrice Martens, MD, PhD



INTEGRATING ICOSAPENT ETHYL IN CARDIOVASCULAR RISK REDUCTION STRATEGIES:
PRACTICAL GUIDANCE

10' education - Oct. 16, 2023 - Pam Taub, MD



EXPLORING THE ROLE OF A NOVEL CETP INHIBITOR IN LIPID MANAGEMENT

10' education - Oct. 12, 2023 - Roxana Mehran, MD



INTERNATIONAL SURVEY OF SECONDARY PREVENTION OF CHD

5' education - Oct. 11, 2023 - John W. McEvoy, MD, PhD, and Joris Holtrop, MD



PERSPECTIVES ON THE RESULTS OF RECENT CLINICAL OUTCOMES TRIALS WITH EPA

10' education - Oct. 9, 2023 - Gabriel Steg



NEW INSIGHTS ON CETP INHIBITION FROM GENETIC RESEARCH AND CLINICAL TRIALS

10' education - Oct. 5, 2023 - John Kastelein, MD, PhD



IMPROVING QUALITY OF LIFE IN PATIENTS WITH HCM

10' education - Oct. 5, 2023 - Carolyn Ho, MD



NEW DIAGNOSTIC STRATEGY TO IMPROVE EARLY CVD DIAGNOSIS IN PRIMARY CARE PATIENTS
WITH COPD OR T2D

3' education - Oct. 4, 2023 - Amy Groenewegen, MD



DIAGNOSTIC CHALLENGES FOR SYMPTOMATIC OBSTRUCTIVE HCM

10' education - Oct. 3, 2023 - Pablo García-Pavia, MD, PhD



ORAL CHOLESTEROL-LOWERING THERAPIES: THE BASIS OF PREVENTION

10' education - Oct. 2, 2023 - Lale Tokgözoğlu, MD



NOVEL APPROACHES IN MANAGING PATIENTS WITH HCM

10' education - Oct. 1, 2023 - Iacopo Olivotto, MD



MANAGEMENT OF PATIENTS WITH CKD AND HF COMPLICATED BY HYPERKALEMIA

15' education - Sep. 28, 2023 - Ellie Kelepouris, MD, and Stephen J. Greene, MD



UPDATED ESC HF GUIDELINES FOR THE MANAGEMENT OF IRON DEFICIENCY IN HF

5' education - Sep. 28, 2023 - Marco Metra, MD



WHAT IS THE TOTALITY OF EVIDENCE FOR IV IRON TREATMENT OUTCOMES IN PATIENTS WITH
HF?

15' education - Sep. 28, 2023 - Giuseppe M.C. Rosano, MD, PhD, Antoni
Bayés-Genís, MD, PhD, and Ovidiu Chioncel, MD, PhD



DIAGNOSING HCM: WHAT A CARDIOLOGIST NEEDS TO KNOW

10' education - Sep. 26, 2023 - Aleš Linhart, MD, PhD



THE KEY ROLE OF RAASI THERAPY IN PATIENTS WITH HF

10' education - Sep. 26, 2023 - Shelley Zieroth, MD
◁2 of 20▷


EFFECTS OF SGLT2 INHIBITOR NOT MODIFIED BY THE COEXISTENCE OF AF IN PATIENTS
WITH HFPEF




Literature - Oct. 24, 2023 - Filippatos G, et al. - Eur J Heart Fail. 2023

In a secondary analysis of the EMPEROR-Preserved trial, the beneficial effects
of empagliflozin on cardiovascular and renal outcomes were consistent in
patients with HFpEF regardless of AF.


HIGH AND INCREASING PREVALENCE OF CARDIO-RENAL-METABOLIC MULTIMORBIDITY




Literature - Oct. 23, 2023 - Ostrominski JW, et al. - JAMA Cardiol. 2023

A population-based cohort study showed that cardio-renal-metabolic conditions
(CVD, CKD, and T2D) and their overlap were increasingly common among US adults
over the last 2 decades.


2023 ESC GUIDELINE UPDATES: WHERE ARE WE WITH IRON DEFICIENCY?




10' education - Oct. 23, 2023 - Giuseppe M.C. Rosano, MD, PhD, Marco Metra, MD,
and Gianluigi Savarese, MD, PhD

What is new in the 2023 ESC Guideline Update regarding iron deficiency in HF? A
panel of experts discuss what the updates mean to clinical practice in the use
of IV iron therapy.


QUITTING SMOKING ASSOCIATED WITH REDUCED RISK OF ADVERSE OUTCOMES AFTER PCI




Literature - Oct. 19, 2023 - Ki YJ, et al. - Eur Heart J. 2023

In a Korean, large-scale, population-based cohort study in the contemporary
drug-eluting stent era, smoking was associated with an increased rate of major
adverse CV and cerebrovascular events in patients undergoing PCI compared with
non-smoking. Quitting smoking after PCI lowered that risk.


A PRACTICAL LOOK AT CARDIORENAL PROTECTION FOR CKD IN T2D: APPLYING RECENT DATA




15' education - Oct. 19, 2023 - Carolyn Lam, MD, PhD, Maria Luiza Caramori, MD,
PhD, Ana Maria Cebrián-Cuenca, MD, PhD, and Pam Taub, MD

How do you achieve optimal outcomes in patients with CKD in T2D? In this video,
a multidisciplinary panel discusses how to improve cardiorenal outcomes in
patients with CKD and T2D.


A MULTIDISCIPLINARY APPROACH TO MANAGING POTASSIUM LEVELS IN PATIENTS WITH HF
WHEN OPTIMIZING RAASI THERAPY




10' education - Oct. 18, 2023 - Antoni Bayés-Genís, MD, PhD, and Patrick
Rossignol, MD, PhD

Patients with HF and multiple comorbidities are complex. Patrick Rossignol and
Antoni Bayés-Genís discuss how to manage hyperkalemia in these complex patients
to enable optimization of RAASi therapy.


NOVEL ORAL PATHWAYS IN LDL-C LOWERING THERAPY: THE NEW PROMISE OF CETPI




10' education - Oct. 17, 2023 - Erin Michos, MD

Erin Michos talks about CETPi as a novel opportunity for oral LDL-c lowering
therapy. She explains the working mechanism of CETPi and discusses past and
ongoing studies with CETPi.


PCSK9I: BENEFITS ACROSS THE SPECTRUM OF CARDIOVASCULAR DISEASE




10' education - Oct. 16, 2023 - Fabrice Martens, MD, PhD

Good risk stratification and optimal LDL-c lowering are key elements in treating
patients at high CV risk. Fabrice Martens gives an overview of the effects
PCSK9i in lowering LDL-c and CV risk.


DISCONTINUATION OF DUAL GIP AND GLP-1 RECEPTOR AGONIST LEADS TO WEIGHT REGAIN IN
PEOPLE WITH OBESITY OR OVERWEIGHT




News - Oct. 16, 2023

EASD 2023 In the SURMOUNT-4 trial, patients on 36-weeks of treatment with
tirzepatide at maximally tolerated doses (10 mg or 15 mg) were randomized to
continued therapy or discontinuation of therapy with placebo to assess whether
body weight reductions by tirzepatide are maintained in people with obesity or
overweight.


LESS PRESCRIPTION OF POTENT P2Y₁₂I AND WORSE OUTCOMES IN WOMEN WITH STEMI VERSUS
MEN




Literature - Oct. 16, 2023 - Burgess SN, et al. - Circ Cardiovasc Interv. 2023

A large observational study on STEMI patients undergoing primary PCI showed
women were less likely to receive potent P2Y₁₂ inhibitors and had higher rates
of in-hospital mortality and major bleeding and major adverse CV and
cerebrovascular events compared with men.


INTEGRATING ICOSAPENT ETHYL IN CARDIOVASCULAR RISK REDUCTION STRATEGIES:
PRACTICAL GUIDANCE




10' education - Oct. 16, 2023 - Pam Taub, MD

Pam Taub talks about how to integrate icosapent ethyl in the day-to-day clinical
practice to reduce cardiovascular risk.


META-ANALYSIS ON THE EFFECT OF BEMPEDOIC ACID IN HYPERLIPIDEMIA




Literature - Oct. 16, 2023 - Mutschlechner D, et al. - Eur Heart J Cardiovasc
Pharmacother. 2023

In a systematic review and meta-analysis, bempedoic acid reduced the rate of
nonfatal MI compared with placebo in hyperlipidemia patients but had no
significant effect on all-cause mortality or stroke. Bempedoic acid was
associated with few side effects.

More


3'+5' EDUCATION


INTERNATIONAL SURVEY OF SECONDARY PREVENTION OF CHD

5' education - Oct. 11, 2023 - John W. McEvoy, MD, PhD, and Joris Holtrop, MD



NEW DIAGNOSTIC STRATEGY TO IMPROVE EARLY CVD DIAGNOSIS IN PRIMARY CARE PATIENTS
WITH COPD OR T2D

3' education - Oct. 4, 2023 - Amy Groenewegen, MD



UPDATED ESC HF GUIDELINES FOR THE MANAGEMENT OF IRON DEFICIENCY IN HF

5' education - Sep. 28, 2023 - Marco Metra, MD



DEVELOPMENT OF THE SCORE2-ASIA CVD RISK PREDICTION ALGORITHM

3' education - Sep. 25, 2023 - Sofian Johar, MD, PhD and Steven Hageman, MD, PhD



HEALTHY LIFESTYLE INTERVENTIONS FOR CVD RISK REDUCTION IN SECONDARY PREVENTION

3' education - Sep. 25, 2023 - Ruxandra Maria Christodorescu, MD and Nadia
Bonekamp, MD

Show more


10'+15' EDUCATION


2023 ESC GUIDELINE UPDATES: WHERE ARE WE WITH IRON DEFICIENCY?

10' education - Oct. 23, 2023 - Giuseppe M.C. Rosano, MD, PhD, Marco Metra, MD,
and Gianluigi Savarese, MD, PhD



A PRACTICAL LOOK AT CARDIORENAL PROTECTION FOR CKD IN T2D: APPLYING RECENT DATA

15' education - Oct. 19, 2023 - Carolyn Lam, MD, PhD, Maria Luiza Caramori, MD,
PhD, Ana Maria Cebrián-Cuenca, MD, PhD, and Pam Taub, MD



A MULTIDISCIPLINARY APPROACH TO MANAGING POTASSIUM LEVELS IN PATIENTS WITH HF
WHEN OPTIMIZING RAASI THERAPY

10' education - Oct. 18, 2023 - Antoni Bayés-Genís, MD, PhD, and Patrick
Rossignol, MD, PhD



NOVEL ORAL PATHWAYS IN LDL-C LOWERING THERAPY: THE NEW PROMISE OF CETPI

10' education - Oct. 17, 2023 - Erin Michos, MD



PCSK9I: BENEFITS ACROSS THE SPECTRUM OF CARDIOVASCULAR DISEASE

10' education - Oct. 16, 2023 - Fabrice Martens, MD, PhD

Show more


AGENDA

Show more


CONTINUE READING:


ANTICOAGULATION


INTERNATIONAL SURVEY OF SECONDARY PREVENTION OF CHD

5' education - Oct. 11, 2023 - John W. McEvoy, MD, PhD, and Joris Holtrop, MD



WHAT IS THE BEST ANTITHROMBOTIC TREATMENT POST-PCI?

3' education - Sep. 21, 2023 - Marco Valgimigli, MD, PhD



PHASE 2 STUDY WITH FXI INHIBITOR IN AF STOPPED EARLY DUE TO OVERWHELMING
EFFICACY

News - Sep. 19, 2023


DIABETES & CVD


HIGH AND INCREASING PREVALENCE OF CARDIO-RENAL-METABOLIC MULTIMORBIDITY

Literature - Oct. 23, 2023 - Ostrominski JW, et al. - JAMA Cardiol. 2023


A PRACTICAL LOOK AT CARDIORENAL PROTECTION FOR CKD IN T2D: APPLYING RECENT DATA

15' education - Oct. 19, 2023 - Carolyn Lam, MD, PhD, Maria Luiza Caramori, MD,
PhD, Ana Maria Cebrián-Cuenca, MD, PhD, and Pam Taub, MD



A MULTIDISCIPLINARY APPROACH TO MANAGING POTASSIUM LEVELS IN PATIENTS WITH HF
WHEN OPTIMIZING RAASI THERAPY

10' education - Oct. 18, 2023 - Antoni Bayés-Genís, MD, PhD, and Patrick
Rossignol, MD, PhD



HEART FAILURE


EFFECTS OF SGLT2 INHIBITOR NOT MODIFIED BY THE COEXISTENCE OF AF IN PATIENTS
WITH HFPEF

Literature - Oct. 24, 2023 - Filippatos G, et al. - Eur J Heart Fail. 2023


2023 ESC GUIDELINE UPDATES: WHERE ARE WE WITH IRON DEFICIENCY?

10' education - Oct. 23, 2023 - Giuseppe M.C. Rosano, MD, PhD, Marco Metra, MD,
and Gianluigi Savarese, MD, PhD



A MULTIDISCIPLINARY APPROACH TO MANAGING POTASSIUM LEVELS IN PATIENTS WITH HF
WHEN OPTIMIZING RAASI THERAPY

10' education - Oct. 18, 2023 - Antoni Bayés-Genís, MD, PhD, and Patrick
Rossignol, MD, PhD



KIDNEY DISEASE & CVD


HIGH AND INCREASING PREVALENCE OF CARDIO-RENAL-METABOLIC MULTIMORBIDITY

Literature - Oct. 23, 2023 - Ostrominski JW, et al. - JAMA Cardiol. 2023


A PRACTICAL LOOK AT CARDIORENAL PROTECTION FOR CKD IN T2D: APPLYING RECENT DATA

15' education - Oct. 19, 2023 - Carolyn Lam, MD, PhD, Maria Luiza Caramori, MD,
PhD, Ana Maria Cebrián-Cuenca, MD, PhD, and Pam Taub, MD



A MULTIDISCIPLINARY APPROACH TO MANAGING POTASSIUM LEVELS IN PATIENTS WITH HF
WHEN OPTIMIZING RAASI THERAPY

10' education - Oct. 18, 2023 - Antoni Bayés-Genís, MD, PhD, and Patrick
Rossignol, MD, PhD



LIPIDS


NOVEL ORAL PATHWAYS IN LDL-C LOWERING THERAPY: THE NEW PROMISE OF CETPI

10' education - Oct. 17, 2023 - Erin Michos, MD



PCSK9I: BENEFITS ACROSS THE SPECTRUM OF CARDIOVASCULAR DISEASE

10' education - Oct. 16, 2023 - Fabrice Martens, MD, PhD



INTEGRATING ICOSAPENT ETHYL IN CARDIOVASCULAR RISK REDUCTION STRATEGIES:
PRACTICAL GUIDANCE

10' education - Oct. 16, 2023 - Pam Taub, MD

© 2006 - 2023 pace-cme.org - About